Valsartan (Diovan, Novartis) received an expanded indication for reducing cardiovascular mortality in patients who are at high risk due to left ventricular failure or dysfunction after myocardial infarction.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

FDA actions in brief

Newsletter